WO2011006596A3 - Wässrige lösung und gelatinierte zusammensetzung umfassend einen phosphodiesterase-5-inhibitor sowie diesbezügliche verfahren und verwendung - Google Patents

Wässrige lösung und gelatinierte zusammensetzung umfassend einen phosphodiesterase-5-inhibitor sowie diesbezügliche verfahren und verwendung Download PDF

Info

Publication number
WO2011006596A3
WO2011006596A3 PCT/EP2010/004058 EP2010004058W WO2011006596A3 WO 2011006596 A3 WO2011006596 A3 WO 2011006596A3 EP 2010004058 W EP2010004058 W EP 2010004058W WO 2011006596 A3 WO2011006596 A3 WO 2011006596A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphodiesterase
inhibitor
aqueous solution
corresponding methods
gelatinized
Prior art date
Application number
PCT/EP2010/004058
Other languages
English (en)
French (fr)
Other versions
WO2011006596A2 (de
Inventor
Katrin Rimkus
Konstantin Holfinger
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of WO2011006596A2 publication Critical patent/WO2011006596A2/de
Publication of WO2011006596A3 publication Critical patent/WO2011006596A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft wässrige Lösungen und gelatinierte Zusammensetzungen eines Phosphodiesterase-5-Inhibitors, bevorzugt Tadalafil, Verfahren zu deren Herstellung und diesbezügliche Arzneimittel sowie die Verwendung von Gelatine zur Verbesserung der Löslichkeit eines Phosphodiesterase-5-Inhibitors in Wasser.
PCT/EP2010/004058 2009-07-16 2010-07-05 Wässrige lösung und gelatinierte zusammensetzung umfassend einen phosphodiesterase-5-inhibitor sowie diesbezügliche verfahren und verwendung WO2011006596A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009033396A DE102009033396A1 (de) 2009-07-16 2009-07-16 Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009033396.7 2009-07-16

Publications (2)

Publication Number Publication Date
WO2011006596A2 WO2011006596A2 (de) 2011-01-20
WO2011006596A3 true WO2011006596A3 (de) 2011-12-29

Family

ID=42646502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/004058 WO2011006596A2 (de) 2009-07-16 2010-07-05 Wässrige lösung und gelatinierte zusammensetzung umfassend einen phosphodiesterase-5-inhibitor sowie diesbezügliche verfahren und verwendung

Country Status (2)

Country Link
DE (1) DE102009033396A1 (de)
WO (1) WO2011006596A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
MX2013001279A (es) * 2013-01-31 2013-08-26 Miguel Angel Garcia Perez Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
MX369874B (es) * 2013-11-29 2019-11-22 Laboratorios Liomont S A De C V Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel.
KR20190043369A (ko) * 2017-10-18 2019-04-26 주식회사 코아팜바이오 유데나필의 신규한 반고형 제제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1120120A1 (de) * 1998-10-05 2001-08-01 Eisai Co., Ltd. Tableten die sich unmittelbar in der mundhöhle auflösen
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
NO20002097L (no) 1999-04-30 2001-10-26 Lilly Icos Llc Fremstillingsgjenstander
US7182958B1 (en) 1999-08-03 2007-02-27 Lilly Icos Llc. β-carboline pharmaceutical compositions
UA71629C2 (en) 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
EP1898879A1 (de) 2005-06-23 2008-03-19 Schering Corporation Schnell resorbierbare oral formulierungen von pde5-hemmern
KR101140110B1 (ko) 2006-07-07 2012-06-04 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1120120A1 (de) * 1998-10-05 2001-08-01 Eisai Co., Ltd. Tableten die sich unmittelbar in der mundhöhle auflösen
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents

Also Published As

Publication number Publication date
DE102009033396A1 (de) 2011-01-20
WO2011006596A2 (de) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2007147160A3 (en) Aprepitant compositions
MY153880A (en) Proline derivatives as cathepsin inhibitors
MX342440B (es) Derivados fluorados de aminotriazol.
MY153921A (en) Aminopyrazole derivatives
MY160675A (en) Composition and method for polishing polysilicon
IL211889A (en) Pyrazolo pyridine derivatives, preparations containing them and their use as nadph oxidase inhibitors
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
MX2011011011A (es) Preparacion solida.
ZA200908612B (en) 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
WO2009007535A3 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
PT2382198E (pt) Processos e intermediários para a preparação de um inibidor macrocíclico de protease do vhc
MY161601A (en) Films and compositions comprising the same
NZ597483A (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
WO2011006596A3 (de) Wässrige lösung und gelatinierte zusammensetzung umfassend einen phosphodiesterase-5-inhibitor sowie diesbezügliche verfahren und verwendung
CY1109865T1 (el) Συνθεσεις βαλσαρτανης
UA104420C2 (uk) Застосування похідних глутарової кислоти або їх фармацевтично прийнятних солей як протиаритмічних засобів
FR2941952B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
ZA201107883B (en) Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containint these derivatives
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
WO2009152474A3 (en) Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
WO2009030725A3 (en) Azaindoles as inhibitors of soluble adenylate cyclase
PL2010200T3 (pl) Zastosowanie polisacharydów pochodzących z grzybów jako kompozycji farmaceutycznej lub suplementów diety
WO2009124734A3 (en) Substituted sulfonamide derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10729820

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10729820

Country of ref document: EP

Kind code of ref document: A2